These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 34855886)

  • 1. Prospective comparison of CT and 18F-FDG PET/MRI in N and M staging of primary breast cancer patients: Initial results.
    Bruckmann NM; Kirchner J; Morawitz J; Umutlu L; Herrmann K; Bittner AK; Hoffmann O; Mohrmann S; Ingenwerth M; Schaarschmidt BM; Li Y; Stang A; Antoch G; Sawicki LM; Buchbender C
    PLoS One; 2021; 16(12):e0260804. PubMed ID: 34855886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective evaluation of whole-body MRI and
    Bruckmann NM; Sawicki LM; Kirchner J; Martin O; Umutlu L; Herrmann K; Fendler W; Bittner AK; Hoffmann O; Mohrmann S; Dietzel F; Ingenwerth M; Schaarschmidt BM; Li Y; Kowall B; Stang A; Antoch G; Buchbender C
    Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2816-2825. PubMed ID: 32333068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What Is the Comparative Ability of 18F-FDG PET/CT, 99mTc-MDP Skeletal Scintigraphy, and Whole-body MRI as a Staging Investigation to Detect Skeletal Metastases in Patients with Osteosarcoma and Ewing Sarcoma?
    Aryal A; Kumar VS; Shamim SA; Gamanagatti S; Khan SA
    Clin Orthop Relat Res; 2021 Aug; 479(8):1768-1779. PubMed ID: 33635285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients.
    Bruckmann NM; Kirchner J; Umutlu L; Fendler WP; Seifert R; Herrmann K; Bittner AK; Hoffmann O; Mohrmann S; Antke C; Schimmöller L; Ingenwerth M; Breuckmann K; Stang A; Buchbender C; Antoch G; Sawicki LM
    Eur Radiol; 2021 Nov; 31(11):8714-8724. PubMed ID: 33912991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer staging in a single session: whole-body PET/CT mammography.
    Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G
    J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831
    [TBL] [Abstract][Full Text] [Related]  

  • 6. "One-stop-shop" staging: should we prefer FDG-PET/CT or MRI for the detection of bone metastases?
    Heusner T; Gölitz P; Hamami M; Eberhardt W; Esser S; Forsting M; Bockisch A; Antoch G
    Eur J Radiol; 2011 Jun; 78(3):430-5. PubMed ID: 19945240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
    Sawicki LM; Grueneisen J; Schaarschmidt BM; Buchbender C; Nagarajah J; Umutlu L; Antoch G; Kinner S
    Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic value of diffusion-weighted magnetic resonance imaging (DWI) compared to FDG PET/CT for whole-body breast cancer staging.
    Heusner TA; Kuemmel S; Koeninger A; Hamami ME; Hahn S; Quinsten A; Bockisch A; Forsting M; Lauenstein T; Antoch G; Stahl A
    Eur J Nucl Med Mol Imaging; 2010 Jun; 37(6):1077-86. PubMed ID: 20204355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of nodal staging between CT, MRI, and [
    Morawitz J; Bruckmann NM; Dietzel F; Ullrich T; Bittner AK; Hoffmann O; Ruckhäberle E; Mohrmann S; Häberle L; Ingenwerth M; Abrar DB; Sawicki LM; Breuckmann K; Fendler WP; Herrmann K; Buchbender C; Antoch G; Umutlu L; Kirchner J
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):992-1001. PubMed ID: 34476552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET) computed tomography (CT) for the detection of bone, lung, and lymph node metastases in rhabdomyosarcoma.
    Vaarwerk B; Breunis WB; Haveman LM; de Keizer B; Jehanno N; Borgwardt L; van Rijn RR; van den Berg H; Cohen JF; van Dalen EC; Merks JH
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD012325. PubMed ID: 34753195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer.
    Minamimoto R; Loening A; Jamali M; Barkhodari A; Mosci C; Jackson T; Obara P; Taviani V; Gambhir SS; Vasanawala S; Iagaru A
    J Nucl Med; 2015 Dec; 56(12):1862-8. PubMed ID: 26405167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-body
    Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
    Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of whole-body 18F-FDG PET/CT and PET/MRI for distant metastases in patients with malignant tumors: a meta-analysis.
    Zhang C; Liang Z; Liu W; Zeng X; Mo Y
    BMC Cancer; 2023 Jan; 23(1):37. PubMed ID: 36624425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic value of
    Tsuyoshi H; Tsujikawa T; Yamada S; Okazawa H; Yoshida Y
    Cancer Imaging; 2020 Oct; 20(1):75. PubMed ID: 33092631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initial M Staging of Rectal Cancer: FDG PET/MRI with a Hepatocyte-specific Contrast Agent versus Contrast-enhanced CT.
    Yoon JH; Lee JM; Chang W; Kang HJ; Bandos A; Lim HJ; Kang SY; Kang KW; Ryoo SB; Jeong SY; Park KJ
    Radiology; 2020 Feb; 294(2):310-319. PubMed ID: 31793850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of multifocality and axillary nodal involvement in early-stage breast cancer patients using 18F-FDG PET/CT compared to contrast-enhanced and diffusion-weighted magnetic resonance imaging and sentinel node biopsy.
    Ergul N; Kadioglu H; Yildiz S; Yucel SB; Gucin Z; Erdogan EB; Aydin M; Muslumanoglu M
    Acta Radiol; 2015 Aug; 56(8):917-23. PubMed ID: 25013091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the diagnostic performance of 18-FDG-PET/MR compared to PET/CT for the N- and M- staging of breast cancer?
    Botsikas D; Bagetakos I; Picarra M; Da Cunha Afonso Barisits AC; Boudabbous S; Montet X; Lam GT; Mainta I; Kalovidouri A; Becker M
    Eur Radiol; 2019 Apr; 29(4):1787-1798. PubMed ID: 30267154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic performance of 18F-FDG PET/CT, ultrasonography and MRI. Detection of axillary lymph node metastasis in breast cancer patients.
    An YS; Lee DH; Yoon JK; Lee SJ; Kim TH; Kang DK; Kim KS; Jung YS; Yim H
    Nuklearmedizin; 2014; 53(3):89-94. PubMed ID: 24220324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the primary staging of rectal cancer.
    Ozis SE; Soydal C; Akyol C; Can N; Kucuk ON; Yagcı C; Erkek AB; Kuzu MA
    World J Surg Oncol; 2014 Feb; 12():26. PubMed ID: 24484935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.